NCT06868381View on ClinicalTrials.gov

A Trial of Baricitinib in Patients With Cardiac Sarcoidosis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

January 1, 2028

Study Completion Date

April 1, 2028

Conditions
Cardiac Sarcoidosis
Interventions
DRUG

Baricitinib (LY3009104) 4 mg

baricitinib 4 mg tablet taken orally once daily

Trial Locations (1)

94304-2210

Stanford University, Palo Alto

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Stanford University

OTHER

NCT06868381 - A Trial of Baricitinib in Patients With Cardiac Sarcoidosis | Biotech Hunter | Biotech Hunter